Quality of Anticoagulation and Predictors of Outcomes in Patients with Atrial Fibrillation Treated with Vitamin K Antagonists: A Real-World Evidence Analysis

María Asunción Esteve‐Pastor, José Miguel Rivera‐Caravaca, Inmaculada Roldán‐Rabadán, Vanessa Roldán, Javier Muñiz, Paula Raña‐Míguez, Martín Ruiz Ortiz, Ángel Cequier, Vicente Bertoméu, Lina Badimón, Manuel Anguita, Professor Gregory Lip, Francisco Marı́n

Letter2019

Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review

Steve Deitelzweig, Professor Gregory Lip

Article2022

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists

Vanessa Roldán, Lorena Martínez-Montesinos, Raquel López‐Gálvez, Lucía García-Tomás, Professor Gregory Lip, José Miguel Rivera‐Caravaca, Francisco Marı́n

Article2018

A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the “Real-World” vs Clinical Trials

José Miguel Rivera‐Caravaca, María Asunción Esteve‐Pastor, Francisco Marı́n, Mariano Valdés, Vicente Vicente, Vanessa Roldán, Professor Gregory Lip

Article2019

Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation

Hee Tae Yu, Pil‐Sung Yang, Jinseub Hwang, Soorack Ryu, Eunsun Jang, Tae‐Hoon Kim, Jae‐Sun Uhm, Jong‐Youn Kim, Hui‐Nam Pak, Moon‐Hyoung Lee, Professor Gregory Lip, Boyoung Joung

Quality of Anticoagulation and Predictors of Outcomes in Patients with Atrial Fibrillation Treated with Vitamin K Antagonists: A Real-World Evidence Analysis

Discussion(0)

Open reviews(0)

Related publications

Quality of oral anticoagulation with vitamin K antagonists in ‘real-world’ patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry

Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists

A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the “Real-World” vs Clinical Trials

Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation